Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5047526 | 0.88 | ESR1 (0.34) | ESR1 | |
| SCHEMBL5043118 | 0.83 | ALOX5 (0.33) | — | |
| SCHEMBL14415721 | 0.82 | ESR1 (0.33) | ESR1CHRM3 | |
| SCHEMBL5523595 | 0.81 | TSHR (0.30) | — | |
| SCHEMBL5046719 | 0.81 | CRHR1 (0.33) | — | |
| SCHEMBL5048598 | 0.78 | CRHR1 (0.33) | — | |
| SCHEMBL5044956 | 0.77 | CRHR1 (0.30) | — | |
| SCHEMBL5044733 | 0.75 | CRHR1 (0.32) | — | |
| SCHEMBL5517704 | 0.75 | MAP3K14 (0.30) | — | |
| SCHEMBL5045280 | 0.75 | CRHR1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268146-B2 | Ring fused pyrazole derivatives as CRF antagonists | PALO ALTO LLC (US) | 2007-09-11 | — | — | US | claimed |
| US-20060135555-A1 | (3,4-Dihydro-1H-isoquinolin-2-yl)-[2-methyl-7-(2,4,6-trimethyl-phenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-b]pyridin-3-yl]-methanone; Corticotropin releasing factor (CRF); stress-related illnesses, mood disorders such as depression, major depressive disorder, single episode depression | ROCHE PALO ALTO LLC | 2006-06-22 | — | — | US | claimed |
| US-7432283-B2 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432283-B2 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC (US) | 2008-10-07 | — | — | US | disclosed |
| US-7268146-B2 | Ring fused pyrazole derivatives as CRF antagonists | PALO ALTO LLC (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268146-B2 | Ring fused pyrazole derivatives as CRF antagonists | PALO ALTO LLC (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268146-B2 | Ring fused pyrazole derivatives as CRF antagonists | PALO ALTO LLC (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1453832-B1 | RING FUSED PYRAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-08-09 | — | — | EP | disclosed |
| US-20060135555-A1 | (3,4-Dihydro-1H-isoquinolin-2-yl)-[2-methyl-7-(2,4,6-trimethyl-phenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-b]pyridin-3-yl]-methanone; Corticotropin releasing factor (CRF); stress-related illnesses, mood disorders such as depression, major depressive disorder, single episode depression | ROCHE PALO ALTO LLC | 2006-06-22 | — | — | US | disclosed |
| US-20050197330-A1 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC | 2005-09-08 | — | — | US | disclosed |
| US-6821984-B2 | FOR THERAPY OF PSYCHIATRIC DISORDERS AND NEUROLOGICAL DISEASES | SYNTEX (U.S.A.) LLC | 2004-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135555-A1 | (3,4-Dihydro-1H-isoquinolin-2-yl)-[2-methyl-7-(2,4,6-trimethyl-phenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-b]pyridin-3-yl]-methanone; Corticotropin releasing factor (CRF); stress-related illnesses, mood disorders such as depression, major depressive disorder, single episode depression | CRHR1, CRH, CRHR2 | ESR1 611/4885CHRM3 426/4885 |
| US-20050197330-A1 | Heterocyclic GABAA subtype selective receptor modulators | GABRA2, GABRA1, GABRA5 | ESR1 569/4885CHRM3 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.